

BD India unveils rapid molecular technique to detect MDR-TB, infectious diseases

01 September 2022 | News

To enable clinicians to rapidly test for TB and multi-drug resistance (MDR) as a first-line test



BD Diagnostics, a segment of BD Lifesciences, has introduced the BD MAX molecular diagnostic system and the availability of the BD MAX MDR-TB panel in India.

The MAX MDR-TB panel is included in WHO guidelines and now clinicians can use the test to simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria contain mutations associated with resistance to two important first-line drugs - Isoniazid (INH) and Rifampicin (RIF) respectively.

The molecular test enhances the information available to direct the optimal treatment for patients and rules out the need for a separate test for isoniazid (INH) detection.

The BD MAX System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR thereby supporting clinicians in prompt and accurate patient disease diagnoses. The state-of-the-art BD MAX System also empowers laboratories to automate their unique internally developed molecular assays, while accessing a rich and growing menu of world-class assays.